1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Hospital Acquired Pneumonia (HAP) Global Clinical Trials Review, H2, 2014

Hospital Acquired Pneumonia (HAP) Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, “Hospital Acquired Pneumonia (HAP) Global Clinical Trials Review, H2, 2014" provides data on the Hospital Acquired Pneumonia (HAP) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hospital Acquired Pneumonia (HAP). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hospital Acquired Pneumonia (HAP). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Hospital Acquired Pneumonia (HAP) Global Clinical Trials Review, H2, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Hospital Acquired Pneumonia (HAP) 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Hospital Acquired Pneumonia (HAP) to Infectious Disease Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Hospital Acquired Pneumonia (HAP) to Infectious Disease Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Hospital Acquired Pneumonia (HAP) 25
Subjects Recruited Over a Period of Time 29
Clinical Trials by Sponsor Type 30
Prominent Sponsors 31
Top Companies Participating in Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials 32
Prominent Drugs 33
Clinical Trial Profiles 34
Clinical Trial Overview of Top Companies 34
AstraZeneca PLC 34
Clinical Trial Overview of AstraZeneca PLC 34
Cubist Pharmaceuticals, Inc. 35
Clinical Trial Overview of Cubist Pharmaceuticals, Inc. 35
Pfizer Inc. 36
Clinical Trial Overview of Pfizer Inc. 36
Johnson and Johnson 37
Clinical Trial Overview of Johnson and Johnson 37
Evolva Holding SA 38
Clinical Trial Overview of Evolva Holding SA 38
Sanofi 39
Clinical Trial Overview of Sanofi 39
KaloBios Pharmaceuticals, Inc. 40
Clinical Trial Overview of KaloBios Pharmaceuticals, Inc. 40
Merck and Co., Inc. 41
Clinical Trial Overview of Merck and Co., Inc. 41
Janssen Pharmaceuticals, Inc. 42
Clinical Trial Overview of Janssen Pharmaceuticals, Inc. 42
Basilea Pharmaceutica AG 43
Clinical Trial Overview of Basilea Pharmaceutica AG 43
Clinical Trial Overview of Top Institutes / Government 44
University of Thessaly 44
Clinical Trial Overview of University of Thessaly 44
Prince of Songkla University 45
Clinical Trial Overview of Prince of Songkla University 45
Universite Victor Segalen Bordeaux 2 46
Clinical Trial Overview of Universite Victor Segalen Bordeaux 2 46
University of Athens 47
Clinical Trial Overview of University of Athens 47
Denver Health and Hospital Authority 48
Clinical Trial Overview of Denver Health and Hospital Authority 48
St. Joseph's Hospital and Medical Center 49
Clinical Trial Overview of St. Joseph's Hospital and Medical Center 49
Mahidol University 50
Clinical Trial Overview of Mahidol University 50
Arak University of Medical Sciences 51
Clinical Trial Overview of Arak University of Medical Sciences 51
Hospital Pablo Tobon Uribe 52
Clinical Trial Overview of Hospital Pablo Tobon Uribe 52
Hamedan University of Medical Sciences 53
Clinical Trial Overview of Hamedan University of Medical Sciences 53
Five Key Clinical Profiles 54
Appendix 81
Abbreviations 81
Definitions 81
Research Methodology 82
Secondary Research 82
About GlobalData 83
Contact Us 83
Disclaimer 83
Source 83

List of Tables
Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Region, 2014* 7
Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Hospital Acquired Pneumonia (HAP) to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Hospital Acquired Pneumonia (HAP) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Hospital Acquired Pneumonia (HAP) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Hospital Acquired Pneumonia (HAP) to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Hospital Acquired Pneumonia (HAP) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Hospital Acquired Pneumonia (HAP) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26
Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Terminated Clinical Trials, 2014* 27
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 29
Hospital Acquired Pneumonia (HAP) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 30
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 31
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 32
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 33
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 34
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials Market, Global, Clinical Trials by Cubist Pharmaceuticals, Inc., 2014* 35
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 36
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson and Johnson, 2014* 37
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials Market, Global, Clinical Trials by Evolva Holding SA, 2014* 38
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 39
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials Market, Global, Clinical Trials by KaloBios Pharmaceuticals, Inc., 2014* 40
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck and Co., Inc., 2014* 41
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials Market, Global, Clinical Trials by Janssen Pharmaceuticals, Inc., 2014* 42
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials Market, Global, Clinical Trials by Basilea Pharmaceutica AG, 2014* 43
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Thessaly, 2014* 44
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials Market, Global, Clinical Trials by Prince of Songkla University, 2014* 45
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials Market, Global, Clinical Trials by Universite Victor Segalen Bordeaux 2, 2014* 46
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Athens, 2014* 47
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials Market, Global, Clinical Trials by Denver Health and Hospital Authority, 2014* 48
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials Market, Global, Clinical Trials by St. Joseph's Hospital and Medical Center, 2014* 49
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials Market, Global, Clinical Trials by Mahidol University, 2014* 50
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials Market, Global, Clinical Trials by Arak University of Medical Sciences, 2014* 51
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials Market, Global, Clinical Trials by Hospital Pablo Tobon Uribe, 2014* 52
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials Market, Global, Clinical Trials by Hamedan University of Medical Sciences, 2014* 53

List of Figures
Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Hospital Acquired Pneumonia (HAP) to Infectious Disease Clinical Trials, G7 Countries (%), 2014* 15
Hospital Acquired Pneumonia (HAP) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Hospital Acquired Pneumonia (HAP) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Hospital Acquired Pneumonia (HAP) to Infectious Disease Clinical Trials, E7 Countries (%), 2014* 18
Hospital Acquired Pneumonia (HAP) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Hospital Acquired Pneumonia (HAP) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Hospital Acquired Pneumonia (HAP) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 29
Hospital Acquired Pneumonia (HAP) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 30
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 31
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 32
Hospital Acquired Pneumonia (HAP) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 33
GlobalData Methodology 82

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

Ulcerative Colitis: Kol Insight

September 2016 $ 8085

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy Market in Europe

  • November 2016
    19 pages
  • Therapy  

  • Europe  

View report >

Therapy Market and Hypertension Statistics in Asia and the US

  • November 2016
    26 pages
  • Therapy  

    Hypertension  

    Cardiovascular ...  

  • Asia  

    United States  

    Europe  

View report >

Therapy Market in the US - Forecast

  • November 2016
    6 pages
  • Therapy  

    Opioid  

  • United States  

View report >

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.